Last reviewed · How we verify
Full dose of iNTS-TCV — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Full dose of iNTS-TCV (Full dose of iNTS-TCV) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Full dose of iNTS-TCV TARGET | Full dose of iNTS-TCV | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Full dose of iNTS-TCV CI watch — RSS
- Full dose of iNTS-TCV CI watch — Atom
- Full dose of iNTS-TCV CI watch — JSON
- Full dose of iNTS-TCV alone — RSS
Cite this brief
Drug Landscape (2026). Full dose of iNTS-TCV — Competitive Intelligence Brief. https://druglandscape.com/ci/full-dose-of-ints-tcv. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab